Startups
Kira Pharmaceuticals is pioneering complement drug discovery to deliver transformative therapies for people with complement-mediated diseases
Overview
Location
United States, Massachusetts, Cambridge
Total raised
$53.5M
Investors 3
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| RA Capital Management | racap.com | |
| Vivo Capital | vivocapital.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 16, 2024 | Kira Pharmaceuticals to Present Positive Long-term Results of KP104 in Phase 2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Study at the 2024 European Hematology Association (EHA) Hybrid Congress | CAMBRIDGE, Mass., May 16, 2024 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced that it will present positive long-term ... |
| Feb 23, 2021 | Kira Pharmaceuticals Expands Executive Leadership Team with Chief Business Officer, Chief Medical Officer and Chief Commercial Officer, China | |
| Feb 2, 2021 | Kira Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial for P014, a Bifunctional Biologic Medicine | |
| Jan 7, 2021 | Kira Pharmaceuticals Closes $53.5 Million Series B+ Financing | Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announced the first closing of an oversubscribed $53.5 million Series B+ financing. T... |
| Jan 7, 2021 | Kira Pharmaceuticals Announces $53.5 Million Series B+ Financing to Advance LOGIC Drug Discovery Platform and Pipeline of Complement-targeted Therapies | |
| Nov 15, 2020 | Kira Pharmaceuticals Launches with $46M Funding | CAMBRIDGE, MA, Kira Pharmaceuticals announced $46M in investments. >> Click here for more funding data on Kira Pharmaceuticals >> To export Kira Pharmaceuticals funding data to PDF and Excel, click here Kira Pharmaceutica... |
| Nov 12, 2020 | Kira Pharmaceuticals Launches to Pioneer Novel Therapeutics for Complement-Mediated Diseases |
Reviews 0
FAQ about Kira Pharmaceuticals
How much funding has Kira Pharmaceuticals raised?
Kira Pharmaceuticals has raised $53.5M in total across 1 funding round.
Who has invested in Kira Pharmaceuticals?
Parsers VC lists 3 investors of Kira Pharmaceuticals, among them RA Capital Management and Vivo Capital.
What has the press written about Kira Pharmaceuticals?
Parsers VC has collected 8 articles mentioning Kira Pharmaceuticals, among them “Kira Pharmaceuticals to Present Positive Long-term Results of KP104 in Phase 2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Study at the 2024 European Hematolog...” (May 16, 2024) and “Kira Pharmaceuticals Expands Executive Leadership Team with Chief Business Officer, Chief Medical Officer and Chief Commercial Officer, China” (Feb 23, 2021).
Is Kira Pharmaceuticals still active?
Yes, Kira Pharmaceuticals is active; its latest activity on Parsers VC dates from Jun 17, 2024.